Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, Do DV; READ-3 Study Group. Sepah YJ, et al. Among authors: callanan d. Ophthalmology. 2016 Dec;123(12):2581-2587. doi: 10.1016/j.ophtha.2016.08.040. Epub 2016 Oct 1. Ophthalmology. 2016. PMID: 27707550 Clinical Trial.
Reticular drusen associated with geographic atrophy in age-related macular degeneration.
Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, Fleckenstein M, Mukesh BN, Hohman TC, Holz FG; Geographic Atrophy Progression (GAP) Study Group. Schmitz-Valckenberg S, et al. Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):5009-15. doi: 10.1167/iovs.11-7235. Invest Ophthalmol Vis Sci. 2011. PMID: 21498612 Clinical Trial.
Topography of geographic atrophy in age-related macular degeneration.
Mauschitz MM, Fonseca S, Chang P, Göbel AP, Fleckenstein M, Jaffe GJ, Holz FG, Schmitz-Valckenberg S; GAP Study Group. Mauschitz MM, et al. Invest Ophthalmol Vis Sci. 2012 Jul 26;53(8):4932-9. doi: 10.1167/iovs.12-9711. Invest Ophthalmol Vis Sci. 2012. PMID: 22661483
PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration.
Peterson SL, Krishnan A, Patel D, Khanehzar A, Lad A, Shaughnessy J, Ram S, Callanan D, Kunimoto D, Genead MA, Tolentino MJ. Peterson SL, et al. Among authors: callanan d. Pharmaceuticals (Basel). 2024 Apr 17;17(4):517. doi: 10.3390/ph17040517. Pharmaceuticals (Basel). 2024. PMID: 38675477 Free PMC article.
Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials.
Krishnan A, Callanan DG, Sendra VG, Lad A, Christian S, Earla R, Khanehzar A, Tolentino AJ, Vailoces VAS, Greene MK, Scott CJ, Kunimoto DY, Hassan TS, Genead MA, Tolentino MJ. Krishnan A, et al. Among authors: callanan dg. Pharmaceuticals (Basel). 2024 Apr 9;17(4):481. doi: 10.3390/ph17040481. Pharmaceuticals (Basel). 2024. PMID: 38675441 Free PMC article.
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Wykoff CC, et al. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421. JAMA Ophthalmol. 2023. PMID: 37535382
161 results